Adeno-Associated Viral Vectors Market Expected To Grow At 15.6% CAGR Through 2030: What Businesses Need To Know
Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Adeno-Associated Viral Vectors Market Size And Revenue Outlook Through 2030
The adeno-associated viral vectors market has experienced rapid expansion in recent years. It is projected to expand from $3.17 billion in 2025 to $3.72 billion in 2026, achieving a compound annual growth rate (CAGR) of 17.6%. The historical growth of this market can be ascribed to factors such as the early creation of AAV vector platforms, the restricted initial clinical adoption for rare diseases, the introduction of preliminary regulatory guidelines for gene therapy, increased research into genetic disorder treatments, and greater funding for preclinical studies.
The adeno-associated viral vectors market size is anticipated to undergo substantial growth in the coming years, projected to reach $6.65 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 15.6%. This expansion during the forecast period is driven by improvements in capsid engineering and vector design, the proliferation of commercial gene therapy launches, increasing demand for personalized medicine, the broadening scope of global clinical trials, and a surge in partnerships between biotechnology and pharmaceutical companies. Key developments expected throughout this period include the broadening application of AAV-based gene therapies for uncommon genetic conditions, heightened financial commitments towards both in vivo and ex vivo gene delivery technologies, the expanding integration of AAV vectors within immunotherapy, an intensified emphasis on gene therapy initiatives at both clinical and commercial levels, and strengthened regulatory frameworks coupled with greater standardization for gene therapy products.
Get A Free Sample Report With In-Depth Market Insights:
Adeno-Associated Viral Vectors Market Growth Factors Behind Sustained Expansion
The adeno-associated viral vectors market is projected to grow due to the rising occurrence of genetic disorders. These conditions arise from abnormalities in an individual’s DNA, leading to physical or developmental issues. The increase in genetic disorder prevalence is attributed to improved diagnostic techniques, greater awareness, a higher reproductive age, as well as environmental factors and genetic drift. Adeno-associated viral vectors are employed in gene therapy for genetic disorders, delivering corrective genes into target cells to potentially treat conditions such as muscular dystrophy or cystic fibrosis. For instance, in February 2023, the World Health Organization (WHO), a Switzerland-based specialized agency of the United Nations responsible for international public health, reported that congenital diseases caused an estimated 240,000 baby deaths globally within 28 days of birth each year. An additional 170,000 children between the ages of 1 month and 5 years die as a result of congenital diseases. Thus, the increasing prevalence of genetic disorders is a significant driver for the adeno-associated viral vectors market.
Adeno-Associated Viral Vectors Market Segment Analysis Spotlighting Growth Areas
The adeno-associated viral vectors market covered in this report is segmented –
1) By Type Of Therapy: Gene Augmentation, Immunotherapy, Other Type Of Therapies
2) By Type Of Gene Delivery Method Used: Ex Vivo, In Vivo
3) By Target Therapeutic Area: Genetic Disorders, Hematological Disorders, Infectious Diseases, Metabolic Disorders, Ophthalmic Disorders, Muscle Disorders, Neurological Disorders, Other Target Therapeutic Areas
4) By Scale Of Operation: Preclinical, Clinical, Commercial
5) By Application Area: Gene Therapy, Cell Therapy, Vaccines
Subsegments:
1) By Gene Augmentation: Inherited Genetic Disorders, Muscular Dystrophy, Cystic Fibrosis, Hemophilia
2) By Immunotherapy: Cancer Immunotherapy, Viral Infections Immunotherapy
3) By Other Types Of Therapies: Gene Editing, RNA Therapy
Adeno-Associated Viral Vectors Market Industry Trends Fueling Future Revenue Growth
Leading companies in the adeno-associated viral vectors market are concentrating on providing off-the-shelf replication-capsid plasmids to secure a competitive advantage. Rep/Cap plasmids, crucial for adeno-associated virus (AAV) vector production in gene therapy, are readily obtainable from numerous commercial suppliers addressing molecular biology research demands. For example, in January 2024, Charles River Laboratories International Inc., a US-based pharmaceutical company, unveiled an off-the-shelf replication-capsid plasmid series that streamlines AAV-based gene therapy efforts. This expansion of their product offerings complements existing lentiviral packaging and AAV Helper plasmid options, reducing manufacturing time by up to 66%. These ready-to-use plasmids are produced in batches with detailed documentation, adhering to CMC guidelines and provided with a Certificate of Analysis (COA) to facilitate Investigational New Drug (IND) and Clinical Trial Application (CTA) submissions.
Adeno-Associated Viral Vectors Market Leading Companies: Who Holds The Strongest Market Presence?
Major companies operating in the adeno-associated viral vectors market are Pfizer Inc., Astellas Pharma, Biogen Inc., Charles River Laboratories International Inc., BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., PTC Therapeutics, Ultragenyx Pharmaceutical, Amicus Therapeutics Inc., Oxford Biomedica, Asklepios BioPharmaceutical Inc., uniQure biopharma B.V., Spark Therapeutics Inc., Akouos Inc., Adverum Biotechnologies Inc., Passage Bio Inc., AVROBIO Inc., MeiraGTx Holdings plc, GenSight Biologics S.A., Freeline Therapeutics, Aspa Therapeutics Inc., Adrenas Therapeutics Inc., 4D Molecular Therapeutics, Abeona Therapeutics Inc., Neurophth Therapeutics
View The Full Adeno-Associated Viral Vectors Market Report:
Adeno-Associated Viral Vectors Market Geographic Spread And Regional Opportunities
North America was the largest region in the adeno-associated viral vectors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adeno-associated viral vectors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
